<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03065023</url>
  </required_header>
  <id_info>
    <org_study_id>RGT100-001</org_study_id>
    <secondary_id>2016-003028-22</secondary_id>
    <nct_id>NCT03065023</nct_id>
  </id_info>
  <brief_title>Phase I/II Trial of Intralesional Administration of RGT100</brief_title>
  <official_title>A Phase I/II, Multicenter, Open-label, Clinical Trial of Intratumoral/Intralesional Administration of RGT100 in Subjects With Advanced or Recurrent Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rigontec GMBH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rigontec GMBH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase I/II multicenter, first-in-human open-label, dose escalation study to
      evaluate the safety, tolerability, and anti-tumor activity of intratumoral/intralesional
      injections of RGT100-PEI in subjects with selected advanced or recurrent tumors.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 25, 2017</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The study will be conducted in 2 groups
Group A: subjects with transdermally/transmucosally injectable tumors
Group B: subjects with injectable liver tumors or liver metastases</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability)</measure>
    <time_frame>For the treatment duration of 4 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of serious adverse events (SAEs)</measure>
    <time_frame>For the treatment duration of 4 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of treatment discontinuation due to treatment-related AEs</measure>
    <time_frame>For the treatment duration of 4 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence and severity of dose-limiting toxicities (DLTs)</measure>
    <time_frame>For the treatment duration of 4 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response rate as evaluated radiologically using immune-related Response Evaluation Criteria in Solid Tumors (irRECIST)</measure>
    <time_frame>Up to 60 days (Week 13) after last injection</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Type of cytokine release in plasma upon treatment</measure>
    <time_frame>Until 30 days (Week 9) after last injection</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Plasma concentrations of RGT100-PEI (AUC)</measure>
    <time_frame>For the treatment duration of 4 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Plasma concentrations of RGT100-PEI (Cmax)</measure>
    <time_frame>For the treatment duration of 4 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Evidence of immune infiltration of injected tumors</measure>
    <time_frame>For the treatment duration of 4 weeks</time_frame>
    <description>Presence of tumor infiltrating immune cells in biopsy (e.g. CD4, CD8)</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">54</enrollment>
  <condition>Advanced Solid Tumors</condition>
  <arm_group>
    <arm_group_label>Group A: Cutaenous lesions</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with transdermally/transmucosally injectable tumors including cutaneous, sub-cutaneous or lymph node injectable tumors.
RGT100-PEI will be injected intratumorally/intralesionally twice a week over a period of 4 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B: Liver lesions</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with injectable liver tumors or liver metastases.
RGT100-PEI will be injected into liver lesions once a week over a period of 4 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RGT100-PEI</intervention_name>
    <description>RGT100-PEI with a fixed concentration of 0.2 mg/mL</description>
    <arm_group_label>Group A: Cutaenous lesions</arm_group_label>
    <arm_group_label>Group B: Liver lesions</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female aged ≥ 18 years

          2. Subjects with histologically or cytologically confirmed diagnosis of advanced or
             recurrent tumors (including lymphomas) for whom all standard treatments have been used
             or are not feasible and RGT100-PEI is a suitable treatment option and:

               1. For Group A: has cutaneous, sub-cutaneous (s.c.), or lymph node injectable tumors

               2. For Group B: has injectable liver tumors or liver metastases

          3. Eastern Cooperative Oncology Group (ECOG) performance status 0-2

          4. Life expectancy &gt; 3 months as assessed by the Investigator

          5. Adequate organ function:

               1. Bone marrow function: Hemoglobin ≥ 10 g/dL (pre-treatment transfusion allowed);
                  lymphocyte count ≥ 0.5 × 109/L; absolute neutrophil count ≥ 0.5 × 109/L; platelet
                  count ≥ 75 × 109/L

               2. Hepatic function: AST and ALT ≤ 2 × upper limit of normal (ULN) (3 × ULN in the
                  case of liver metastases); bilirubin ≤ 1.5 × ULN (2 × ULN in case of liver
                  metastases)

               3. Renal function: creatinine &lt; 1.5 × ULN and/or creatinine clearance ≥ 50 mL/min
                  (Cockroft and Gault)

          6. Negative serum pregnancy test within 2 weeks before first dose of study drug if the
             subject is a woman of childbearing potential. Subjects and subjects' partners of
             childbearing potential must agree to use birth control consistently and correctly
             during the study and for at least 6 months after the last study drug application.

          7. At least 1 measurable lesion per RECIST 1.1 and 1 separate injectable lesion with
             diameter ≥ 1 cm but &lt; 7 cm

          8. Ability to provide written informed consent before any study drug-related screening
             procedures being performed

        Exclusion Criteria:

          1. Any tumor-directed therapy within 4 weeks before study treatment

          2. Treatment with investigational drugs within 4 weeks before study enrolment

          3. Systemic steroids at a dose of &gt; 10 mg of prednisolone, &gt; 2 mg of dexamethasone a day
             or equivalent, except topical (inhaled, topical, nasal) for the last 28 days and
             ongoing

          4. Subjects with rapidly progressing disease (as determined by the Investigator)

          5. Ongoing immune-related adverse events (irAEs) and/or AEs ≥ grade 2 not resolved from
             previous therapies except vitiligo, stable neuropathy grade 2, hair loss, and stable
             endocrinopathies with substitutive hormone therapy

          6. Within 4 weeks of major surgery

          7. Prior splenectomy

          8. Documented history of active autoimmune disorders requiring systemic immunosuppressive
             therapy

          9. Primary or secondary immune deficiency

         10. Active allergy requiring systemic medication or active infections requiring
             anti-infectious therapy

         11. Seropositive (except after vaccination) for human immunodeficiency virus (HIV),
             hepatitis B virus (HBV) or hepatitis C virus (HCV)

         12. Clinically significant cardiac disease including heart failure (New York Heart
             Association, Class III or IV), pre-existing arrhythmia, uncontrolled angina pectoris,
             or myocardial infarction within 1 year before study entry

         13. Dementia or altered mental status that would prohibit informed consent

         14. Other severe, acute, or chronic medical or psychiatric condition or laboratory
             abnormality that may increase the risk associated with study assessed by the
             Investigator

         15. History of stroke, seizures, encephalitis, or multiple sclerosis

         16. Gastric ulcer or inflammatory bowel disease or Crohn's disease or ulcerative colitis
             in the last 6 months

         17. Active drug or alcohol abuse

         18. Pregnant or breast feeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Manuela Niewel, Dr.</last_name>
    <role>Study Director</role>
    <affiliation>Rigontec GMBH</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mark Middleton, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Oxford Department of Oncology, Churchill Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universitätsklinikum Carl Gustav Carus - Phase I Unit</name>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Essen</name>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Center for Tumor Diseases</name>
      <address>
        <city>Heidelberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>START - Fundación Jiménez Díaz - Phase I Unit</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>START - Hospital Universitario HM Sanchinarro - Phase I Unit</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Oxford Department of Oncology, Churchill Hospital</name>
      <address>
        <city>Oxford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 10, 2017</study_first_submitted>
  <study_first_submitted_qc>February 21, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 27, 2017</study_first_posted>
  <last_update_submitted>May 2, 2018</last_update_submitted>
  <last_update_submitted_qc>May 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>advanced tumor</keyword>
  <keyword>intratumoral injection</keyword>
  <keyword>intralesional injection</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

